Core Insights - The article highlights a landmark meeting co-sponsored by LIXTE Biotechnology Holdings, focusing on the activation of oncogenic signaling as a novel cancer treatment strategy [1][2] - LIXTE's lead compound, LB-100, was presented as a first-in-class PP2A inhibitor that activates oncogenic signaling, leading to cancer cell toxicity [2][4] Group 1: Conference Highlights - The conference introduced a paradigm shift in cancer therapy, advocating for the activation of oncogenic pathways rather than solely inhibiting them [3] - LB-100 exemplifies this approach by inhibiting PP2A, which removes a cellular "off switch," resulting in uncontrolled signaling that drives cancer cells to self-destruction [4] - Presentations at the conference reinforced the recognition of PP2A inhibition as a new therapeutic frontier, supporting LB-100's role as a platform therapy [5] Group 2: Company Positioning - By co-sponsoring the meeting, LIXTE positioned itself as a global thought leader in innovative cancer therapies, demonstrating its commitment to advancing cancer research [6] - LIXTE is focused on developing therapies targeting the PP2A pathway, with LB-100 showing strong preclinical results and early-stage clinical tolerability [7] - The company is currently advancing a proof-of-concept trial in Ovarian Clear Cell Carcinoma, indicating its active role in clinical development [7]